medwireNews@ESMO2017

The findings of the ALUR trial and of an additional analysis of the ALEX trial confirm the benefits of treatment with the second-generation anaplastic lymphoma kinase inhibitor alectinib in patients with advanced ALK-positive non-small-cell lung cancer.

Hyperprogression can occur following treatment with agents targeting programmed cell death protein 1 or its ligand, shows a review of patients with advanced non-small-cell lung cancer.

Lurbinectedin has potential for the treatment of patients with relapsed small-cell lung cancer as a single agent or in combination with another chemotherapy drug, suggests research reported at the ESMO 2017 Congress in Madrid, Spain.

Perioperative docetaxel, oxaliplatin, and 5-fluorouracil/leucovorin treatment should be a new standard of care for patients with operable adenocarcinoma of the stomach or gastroesophageal junction, say the FLOT4-AIO trial investigators.

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

Central obesity is associated with an increased incidence of cancer in postmenopausal women, according to research presented at the ESMO 2017 Congress in Madrid, Spain.

Hyperprogression can occur following treatment with agents targeting programmed cell death protein 1 or its ligand, shows a review of patients with advanced non-small-cell lung cancer.

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

Central obesity is associated with an increased incidence of cancer in postmenopausal women, according to research presented at the ESMO 2017 Congress in Madrid, Spain.